Patient-derived response estimates from zero-passage organoids of luminal breast cancer
Zero-passage organoids are a rapid and scalable way to interrogate properties of luminal breast cancer cells from patient-derived material. This includes testing drug mechanisms of action in different clinical cohorts. A future goal is to relate inter-patient variability of zero-passage organoids to long-term outcomes.
Authors
- Kevin A. Janes (ORCID: https://orcid.org/0000-0002-8028-6138)
- Piotr Przanowski (ORCID: https://orcid.org/0000-0002-9191-4769)
- R. Hawes (ORCID: https://orcid.org/0000-0001-9087-9079)
- Shayna L. Showalter (ORCID: https://orcid.org/0000-0001-7950-759X)
- Kristen A. Atkins (ORCID: https://orcid.org/0000-0003-1022-9629)
- Róża K. Przanowska (ORCID: https://orcid.org/0000-0003-1278-6242)
- Najwa Labban (ORCID: https://orcid.org/0000-0003-0021-2591)
Institutions
- University of Virginia Health System (US)
- University of Virginia (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1186/s13058-024-01931-5
- Citations
- 4
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.14
Funders
- University of Virginia
- National Institutes of Health